Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5)

International Journal of Impotence Research

Volumn 16, Issue 5, 2004, Pages 412-417

  Salvi, F ^a,b   Sarzani, R ^a   Giorgi, R ^a   Donatelli, G ^a   Pietrucci, F ^a   Micheli, A ^a   Baldoni, M ^a   Minaroli, D ^a   Dessi Fulgheri P ^a   Polito, M ^a   Muzzonigro, G ^a   Rappelli, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Clinica di Medicina Interna   (Italy)

Author keywords

Erectile dysfunction; Hypertension; PDE5 alleles; Sildenafil

Indexed keywords

CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; GUANINE; SILDENAFIL; THYMINE;

ADULT; ALLELE; ARTERY MUSCLE; ARTICLE; BLOOD PRESSURE; DRUG EFFECT; DRUG RESPONSE; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RELAXATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR; SMOOTH MUSCLE CONTRACTILITY; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 5' FLANKING REGION; ADULT; AGED; ALLELES; DNA; GENOTYPE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; IMPOTENCE; MALE; MIDDLE AGED; PIPERAZINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTOR AP-1; VASODILATOR AGENTS;

EID: 4844222662     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901246     Document Type: Article

References (31)

1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54-61.
2. Martin-Morales A et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculine Study. J Urol 2001; 166: 569-574.
3. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001; 21: 676-683.
4. Karadeniz T et al. Correlation of ultrastructural alterations in cavernous tissue with the clinical diagnosis vasculogenic hypertension. Urol Int 1996; 57: 58-61.
5. Burchardt M et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188-1191.
6. McVary KT, Carrier S, Wessels H. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001; 166: 1624-1632.
7. Fedele D et al. Incidence of erectile dysfunction in Italian men with diabetes. J Urol 2001; 166: 1368-1371.
8. Jaffe A et al. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants. Hypertension 1996; 28: 859-862.
9. Wespes E. Smooth muscle pathology and erectile dysfunction. Int J Impot Res 2002; 14(Suppl 1): S17-21.
10. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol 1997; 20: 26-33.
11. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986; 78: 1-5.
12. Garbers DL, Dubois SK. The molecular basis of hypertension. Annu Rev Biochem 1999; 68: 127-155.
13. Saenz De Tejada I. Molecular mechanisms for the regulation of penile smooth muscle contractility. Int J Impot Res 2002; 14(Suppl 1): S6-S10.
14. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-1813.
15. Boolell M et al. An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
16. Morales A et al. Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 1998; 10: 69-74.
17. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 1998; 338: 1397-1404.
18. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000; 342: 1622-1626.
19. Summary of death reports in Viagra received from marketing (late March) through June 1998. Food and Drug Administration (Center for Drug Evaluation and Research): Washington, DC, 1998.
20. Inoue I et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 1997; 99: 1786-1797.
21. Kupari M et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 1998; 97: 569-575.
22. Sarzani R et al. A novel promoter variant of the natriuretic peptide clearance receptor gene is associated with lower ANP and higher blood pressure in obese hypertensives. J Hypertens 1999; 17: 1301-1305.
23. Yanaka N et al. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem 1998; 255: 391-399.
24. Pilz RB et al. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J 1995; 9: 552-558.
25. Pawliczak R et al. p11 expression in human bronchial epithelial cells is increased by nitric oxide in a cGMP-dependent pathway involving protein kinase G activation. J Biol Chem 2001; 276: 44613-44621.
26. Lin CS, Lau A, Tu R, Lue TF. Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Biochem Biophys Res Commun 2000; 268: 628-635.
27. Lin CS et al. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 2001; 280: 684-692.
28. Lin CS et al. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001; 280: 693-699.
29. Lin CS et al. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 2002; 14: 15-24.
30. Zusman RM, Prisant ML, Brown MJ, for the Sildenafil Study Group. Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. J Hypertens 2000; 18: 1865-1869.
31. Arruda-Olson AM et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA 2002; 14: 719-725.